

Davide Campana

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4605317/davide-campana-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122
papers

3,011
citations

30
h-index

52
g-index

137
ext. papers

3,498
ext. citations

3.9
avg, IF

4.64
L-index

#	Paper	IF	Citations
122	Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008 , 35, 1431-8	8.8	220
121	Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2372-7	2.2	216
120	68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 669-73	8.9	197
119	Chromogranin A: is it a useful marker of neuroendocrine tumors?. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1967-73	2.2	183
118	Endocrine pancreatic tumors: factors correlated with survival. <i>Annals of Oncology</i> , 2005 , 16, 1806-10	10.3	154
117	Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 353-9	8.9	133
116	⁶⁸ Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39 Suppl 1, S52-60	8.8	93
115	(68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 722-7	8.8	83
114	Warm water or oil-assisted colonoscopy: toward simpler examinations?. <i>American Journal of Gastroenterology</i> , 2008 , 103, 581-7	0.7	70
113	Real-world study of everolimus in advanced progressive neuroendocrine tumors. <i>Oncologist</i> , 2014 , 19, 966-74	5.7	66
112	Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 1843-8	8.9	58
111	Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? a single-center experience. <i>Pancreas</i> , 2010 , 39, 825-8	2.6	56
110	Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. <i>Endocrine-Related Cancer</i> , 2008 , 15, 337-42	5.7	54
109	Assessment of the quality of life in chronic pancreatitis using Sf-12 and EORTC QLq-C30 questionnaires. <i>Digestive and Liver Disease</i> , 2007 , 39, 1077-86	3.3	50
108	Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 817-23	5.2	48
107	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 1197-205	8.8	44
106	Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. <i>Neuroendocrinology</i> , 2012 , 96, 32-40	5.6	44

105	Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). <i>Annals of Oncology</i> , 2018 , 29, viii467-viii468	10.3	44
104	Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours. <i>Nuclear Medicine Communications</i> , 2007 , 28, 473-7	1.6	43
103	Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. <i>Endocrine</i> , 2018 , 60, 490-498	4	41
102	Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. <i>International Journal of Endocrinology</i> , 2018 , 2018, 8126087	2.7	40
101	Prognostic factors in ectopic Cushing β syndrome due to neuroendocrine tumors: a multicenter study. <i>European Journal of Endocrinology</i> , 2017 , 176, 453-461	6.5	39
100	Endocrine tumors of the ileum: factors correlated with survival. <i>Neuroendocrinology</i> , 2006 , 83, 380-6	5.6	39
99	Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. <i>Pancreas</i> , 2014 , 43, 212-8	2.6	38
98	Everolimus in Pancreatic Neuroendocrine Carcinomas G3. <i>Pancreas</i> , 2017 , 46, 302-305	2.6	37
97	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018 , 155, 479-489.e7	13.3	36
96	Are there prognostic factors related to recurrence in pancreatic endocrine tumors?. <i>Pancreatology</i> , 2010 , 10, 33-8	3.8	33
95	PET/CT with 68Gallium-DOTA-peptides in NET: an overview. <i>European Journal of Radiology</i> , 2011 , 80, e116-9	4.7	32
94	Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. <i>Endocrine</i> , 2016 , 51, 131-9	4	31
93	Is ^{68}Ga -DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 1278-83	8.8	31
92	The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	30
91	Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms. <i>Scandinavian Journal of Gastroenterology</i> , 2010 , 45, 93-9	2.4	29
90	Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas. <i>World Journal of Gastroenterology</i> , 2009 , 15, 5067-73	5.6	28
89	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study. <i>Annals of Surgery</i> , 2020 , 271, 527-533	7.8	27
88	Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. <i>Endocrine</i> , 2017 , 56, 633-638	4	25

87	Sporadic Small (≥ 20 mm) Nonfunctioning Pancreatic Neuroendocrine Neoplasm: is the Risk of Malignancy Negligible When Adopting a More Conservative Strategy? A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2017 , 24, 2603-2610	3.1	24
86	Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours. <i>Pancreatology</i> , 2016 , 16, 403-10	3.8	23
85	Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. <i>Annals of Surgical Oncology</i> , 2018 , 25, 3200-3206	3.1	23
84	The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours. <i>Pancreatology</i> , 2013 , 13, 589-93	3.8	23
83	Chronic asymptomatic pancreatic hyperenzymemia is a benign condition in only half of the cases: a prospective study. <i>Scandinavian Journal of Gastroenterology</i> , 2009 , 44, 888-93	2.4	22
82	Plasma acylated ghrelin levels are higher in patients with chronic atrophic gastritis. <i>Clinical Endocrinology</i> , 2007 , 67, 761-6	3.4	22
81	Adult coeliac disease diagnosed by endoscopic biopsies in the duodenal bulb. <i>European Journal of Gastroenterology and Hepatology</i> , 2005 , 17, 1413-5	2.2	19
80	Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study. <i>Digestive and Liver Disease</i> , 2019 , 51, 1456-1460	3.3	18
79	Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study. <i>Neuroendocrinology</i> , 2016 , 103, 531-7	5.6	18
78	^{68}Ga -DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease. <i>Clinical Nuclear Medicine</i> , 2011 , 36, 64-5	1.7	18
77	Value of both WHO and TNM classification systems for patients with pancreatic endocrine tumors: results of a single-center series. <i>World Journal of Surgery</i> , 2009 , 33, 2458-63	3.3	18
76	Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammation. <i>Journal of Gastroenterology</i> , 2007 , 42, 754-60	6.9	18
75	Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study. <i>Digestive and Liver Disease</i> , 2019 , 51, 689-694	3.3	18
74	Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. <i>Cancers</i> , 2020 , 12,	6.6	18
73	Treatment of Zollinger-Ellison syndrome. <i>World Journal of Gastroenterology</i> , 2005 , 11, 5423-32	5.6	16
72	Is surgery the best treatment for sporadic small (≥ 2 cm) non-functioning pancreatic neuroendocrine tumours? A single centre experience. <i>Pancreatology</i> , 2017 , 17, 471-477	3.8	15
71	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. <i>Pancreatology</i> , 2018 , 18, 198-203	3.8	14
70	WHO 2010 classification of pancreatic endocrine tumors. is the new always better than the old?. <i>Pancreatology</i> , 2014 , 14, 539-41	3.8	14

69	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	14
68	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018 , 25, 607-618	5.7	13
67	The functioning side of the pancreas: a review on insulinomas. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 139-148	5.2	13
66	Evaluation of patient-reported outcome in subjects treated medically for acute pancreatitis: a follow-up study. <i>Pancreatology</i> , 2009 , 9, 375-82	3.8	12
65	Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. <i>Hpb</i> , 2013 , 15, 935-43	3.8	11
64	Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study. <i>European Journal of Endocrinology</i> , 2020 , 182, 439-446	6.5	11
63	Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis. <i>Pancreatology</i> , 2018 , 18, 313-317	3.8	10
62	Pancreatic involvement in systemic sarcoidosis. A case report. <i>Digestive and Liver Disease</i> , 2004 , 36, 222-3	3.3	10
61	The ELISA fecal elastase-1 polyclonal assay reacts with different antigens than those of the monoclonal assay. <i>Pancreas</i> , 2005 , 31, 200-1	2.6	10
60	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. <i>Oncologist</i> , 2020 , 25, 259-265	5.7	9
59	⁶⁸ Ga DOTANOC PET/CT detects primary malignant insulinoma. <i>Clinical Nuclear Medicine</i> , 2015 , 40, e132-37	3.7	9
58	Efficacy and cost-effectiveness of immediate surgery versus a wait-and-see strategy for sporadic nonfunctioning T1 pancreatic endocrine neoplasms. <i>Neuroendocrinology</i> , 2015 , 101, 25-34	5.6	8
57	Histopathological diagnosis of appendiceal neuroendocrine neoplasms: when to perform a right hemicolectomy? A systematic review and meta-analysis. <i>Endocrine</i> , 2019 , 66, 460-466	4	7
56	Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations. <i>Pancreatology</i> , 2019 , 19, 1067-1073	3.8	7
55	Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors. <i>Gastroenterology Research and Practice</i> , 2017 , 2017, 7872519	3.9	7
54	Maffucci Syndrome with Hemangioma of the Liver. <i>Case Reports in Gastroenterology</i> , 2009 , 3, 1-4	1	6
53	Factors related to long-term survival in patients affected by well-differentiated endocrine tumors of the pancreas. <i>ISRN Surgery</i> , 2012 , 2012, 389385		6
52	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. <i>Surgical Oncology</i> , 2020 , 35, 141-148	2.5	6

51	Incidental diagnosis of very small rectal neuroendocrine neoplasms: when should endoscopic submucosal dissection be performed? A single ENETS centre experience. <i>Endocrine</i> , 2019 , 65, 207-212	4	5
50	Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid. <i>Digestive and Liver Disease</i> , 2010 , 42, 457-8	3.3	5
49	Diagnostic value of tumor M2-pyruvate kinase in neuroendocrine tumors. A comparative study with chromogranin A. <i>Anticancer Research</i> , 2003 , 23, 2969-72	2.3	5
48	When should F-18 FDG PET/CT be used instead of 68Ga-DOTA-peptides to investigate metastatic neuroendocrine tumors?. <i>Clinical Nuclear Medicine</i> , 2011 , 36, 1109-11	1.7	4
47	Lubrication during colonoscopy: a forgotten factor. <i>Digestive and Liver Disease</i> , 2005 , 37, 630-1	3.3	4
46	Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
45	An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	4
44	Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis. <i>Endocrine</i> , 2021 , 72, 268-278	4	4
43	Comment on "Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors": A National Study From the French Group of Endocrine Tumors (GTE). <i>Annals of Surgery</i> , 2019 , 270, e43-e44	7.8	3
42	Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms. <i>Journal of Chemotherapy</i> , 2018 , 30, 53-58	2.3	3
41	A meal stimulation test in the diagnosis of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. <i>Endocrine</i> , 2002 , 17, 229-32		3
40	Optimal treatment of Zollinger-Ellison syndrome and related conditions in elderly patients. <i>Drugs and Aging</i> , 2003 , 20, 1019-34	4.7	3
39	Disease-free survival as a measure of overall survival in resected pancreatic endocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2020 , 27, 275-283	5.7	3
38	A [68Ga]Ga-DOTANOC PET/CT Radiomic Model for Non-Invasive Prediction of Tumour Grade in Pancreatic Neuroendocrine Tumours. <i>Diagnostics</i> , 2021 , 11,	3.8	3
37	Therapeutic options in lung neuroendocrine tumors: between established concepts and new hopes. <i>Anti-Cancer Drugs</i> , 2019 , 30, e0784	2.4	3
36	Should we lose hope in adjuvant therapy for neuroendocrine tumors?-In response to: Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. <i>Journal of Surgical Oncology</i> , 2020 , 122, 570-571	2.8	2
35	Basis for treatment of functioning neuroendocrine tumours. <i>Digestive and Liver Disease</i> , 2004 , 36 Suppl 1, S35-41	3.3	2
34	Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?. <i>Anti-Cancer Drugs</i> , 2020 , 31, 1103-1105	2.4	2

33	Patient-reported outcomes in patients with endocrine tumors of the ileum. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 689-94	2.2	2
32	68Ga-DOTANOC PET/CT Detects Multifocal Hepatocellular Carcinoma. <i>Clinical Nuclear Medicine</i> , 2019 , 44, 238-239	1.7	2
31	Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials. <i>Cancers</i> , 2021 , 13,	6.6	2
30	Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1
29	Cutaneous Scapular Lesion in an Elderly Woman. <i>JAMA Oncology</i> , 2019 , 5, 1355-1356	13.4	1
28	Multiple gastrinomas of the duodenum in a patient with sporadic Zollinger-Ellison syndrome. <i>Endocrine</i> , 2013 , 44, 815-6	4	1
27	An acute and severe immunodeficiency syndrome due to a pancreatic ACTH-producing tumor. <i>Emergency Care Journal</i> , 2012 , 8, 19	1.2	1
26	Water-related techniques in colonoscopy: the end justifies the means!. <i>Gastrointestinal Endoscopy</i> , 2009 , 70, 1287-9; author reply 1289	5.2	1
25	Warm water and oil assistance in colonoscopy. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 3286-7; author reply 3287-8	4	1
24	Multiple gastric endocrine tumours and gastrinomas of the duodenum in a patient with ZES MEN 1. <i>Digestive and Liver Disease</i> , 2008 , 40, 476	3.3	1
23	Sedation on demand and lubrication during colonoscopy: should we change our minds?. <i>Gastrointestinal Endoscopy</i> , 2008 , 68, 1028-9; author reply 1029	5.2	1
22	Sedation during colonoscopy and the benefits of lubrication. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 27, 207-8; author reply 208-9	6.1	1
21	Role of [F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors.. <i>Endocrine</i> , 2022 , 1	4	1
20	Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications. <i>Clinical and Translational Imaging</i> , 2021 , 9, 423-438	2	1
19	Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
18	Medical treatment of endocrine gastroenteropancreatic tumors. <i>JOP: Journal of the Pancreas</i> , 2006 , 7, 145-9	1.2	1
17	The 3-Dimensional-Computed Tomography Texture Is Useful to Predict Pancreatic Neuroendocrine Tumor Grading.. <i>Pancreas</i> , 2021 , 50, 1392-1399	2.6	1
16	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.. <i>JAMA Network Open</i> , 2022 , 5, e220290 ^{10.4}		0

- 15 Chromogranin A usefulness in small non-functioning pancreatic neuroendocrine tumors surgical management. *Surgery*, **2019**, 166, 952 3.6
- 14 Therapy for Locoregional Disease: Stomach/Duodenum, Colon/Rectum **2018**, 219-234
- 13 I marcatori neuroendocrini nella pratica clinica: utilit e limiti. *L Endocrinologo*, **2017**, 18, 64-65 0
- 12 Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al. *European Journal of Nuclear Medicine and Molecular Imaging*, **2014**, 41, 176-7 8.8
- 11 Everolimus for the treatment of advanced pancreatic neuroendocrine tumors. *Clinical Investigation*, **2012**, 2, 1123-1131
- 10 Metastatic 5-mm rectal neuroendocrine carcinoma. *Digestive and Liver Disease*, **2011**, 43, e25 3.3
- 9 Warm water and oil for the difficult colon. *Gastrointestinal Endoscopy*, **2009**, 69, 391; author reply 392 5.2
- 8 New WHO classification for pancreatic endocrine tumors: Is time to leave the previous one?. *Journal of Clinical Oncology*, **2012**, 30, e14647-e14647 2.2
- 7 Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.. *Journal of Clinical Oncology*, **2021**, 39, TPS4167-TPS4167 2.2
- 6 Adjuvant chemotherapy in nonmetastatic goblet cell carcinomas: A population-based analysis.. *Journal of Clinical Oncology*, **2021**, 39, e16203-e16203 2.2
- 5 Large cell neuroendocrine carcinoma of the lung: Prognostic factors to predict clinical outcomes.. *Journal of Clinical Oncology*, **2021**, 39, e20515-e20515 2.2
- 4 A cure model survival analysis of patients affected by small intestinal neuroendocrine neoplasms: the Bologna ENETS center experience. *Endocrine*, **2019**, 64, 702-707 4
- 3 Siblings Diagnosed With Primary Neuroendocrine Tumor of the Left Hepatic Duct. *ACG Case Reports Journal*, **2019**, 6, e00104 0.6
- 2 Prophylactic cholecystectomy is not mandatory in patients candidate to the resection for small intestine neuroendocrine neoplasms: a propensity score-matched and cost-minimization analysis. *Updates in Surgery*, **2021**, 1 2.9
- 1 Effect of intravenous infusion of amino acids on pancreatic secretion. *Hepato-Gastroenterology*, **2002**, 49, 822-4